D. Cottrell

发表

The Growing Potential of Neurophysiology in Multiple Sclerosis

Canham Ljw, D. Western, P. Walsh, 2016 .

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Margaret Burnett, Gavin Giovannoni, 2018, The Lancet.

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

David K Howse, A. Verier, M. Valis, 2018, Multiple sclerosis and related disorders.

Primary progressive multiple sclerosis: progress and challenges

D. Cottrell, N. Scolding, A. Wilkins, 2013, Journal of Neurology, Neurosurgery & Psychiatry.

Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)

K. Inglis, D. Cottrell, P. White, 2018, BMC Neurology.

Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.

K. Inglis, D. Cottrell, M. Rolinski, 2018, Multiple sclerosis and related disorders.

Spontaneous intracranial hypotension and venous sinus thrombosis

S. Renowden, D. Cottrell, D. Sandeman, 2013, Practical Neurology.

Does natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion.

S. Renowden, K. Inglis, D. Cottrell, 2013, Multiple sclerosis and related disorders.

Neurochemical and electrophysiological studies on FR115427, a novel non-competitive NMDA receptor antagonist.

S. Butcher, H. J. Olverman, J. Kelly, 1993, European journal of pharmacology.

Handbook of Neurologic Rating Scales. 2nd Edition

D. Cottrell, 2007, Journal of Neurology.

Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial

P. Morgan, Y. Ben-Shlomo, N. Evangelou, 2015, Trials.

A window of opportunity for no treatment in early multiple sclerosis?

D. Cottrell, M. Boggild, N. Scolding, 2010, Multiple sclerosis.

Sub-acute presentation of Morvan ’ s syndrome after thymectomy

D. Birchall, D. Cottrell, S. Barnard, 2004 .

What Are the Participants' Perspectives of Taking Melatonin for the Treatment of Nocturia in Multiple Sclerosis? A Qualitative Study Embedded within a Double-Blind RCT

D. Cottrell, M. Drake, N. Cotterill, 2018, Multiple Sclerosis International.

Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS)

K. Inglis, D. Cottrell, P. White, 2017, BMC Neurology.

Multimodal neurophysiological evaluation of primary progressive multiple sclerosis - An increasingly valid biomarker, with limits.

P. Walsh, N. Kane, K. Inglis, 2015, Multiple sclerosis and related disorders.

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

J. Baskerville, G. Rice, G. Ebers, 1999, Brain : a journal of neurology.

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.

J. Baskerville, G. Rice, G. Ebers, 1999, Brain : a journal of neurology.